International trends in clozapine use: a study in 17 countries

Bachmann, C. J., Aagaard, L., Bernardo, M., Brandt, L., Cartabia, M., Clavenna, A., Coma Fusté, A., Furu, K. +26 more·2017·Acta Psychiatrica Scandinavica
DOI 10.1111/acps.12742

Cited by (312)

Items 201–300 of 312

  1. Clozapine prescribing in Germany: temporal trends and regional variations, 2012–2022
    Oliver H. F. Scholle, Oliver Riedel, Mishal Qubad, Michael Dörks, Bianca Kollhorst, Robert A. Bittner, Christian Bachmann · 2026 · Schizophrenia
  2. History of suicidal behavior and clozapine prescribing among people with schizophrenia in China: a cohort study
    Yi Yin, Lin Chen, Lijing Wei, Jinghui Tong, Junchao Huang, Baopeng Tian, Shuping Tan, Zhiren Wang, Fude Yang, Yongsheng Tong et al. · 2024 · BMC Psychiatry
  3. Clozapine: old drugs require efforts to improve patient experience and access
    Jack B. Fanshawe, Thomas Kabir, Belinda Lennox · 2025 · The Lancet
  4. Long-term trajectories of treatment-resistant schizophrenia following clozapine or electroconvulsive therapy: A retrospective observational study
    Hirotsugu Kawashima, Yoshiteru Takekita, Nobuatsu Aoki, Masaaki Hazama, Morio Aki, Kentaro Katsuragi, Takaaki Ando, Hiroto Sakai, Aran Tajika, Toshiya Murai et al. · 2025 · Journal of Psychiatric Research
  5. Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics
    Fuminari Misawa, Ami Amemiya, 康男 藤井, Hiroyoshi Takeuchi · 2021 · Journal of Clinical Psychopharmacology
  6. Clozapine shared care: mental health services and GPs working together for better outcomes for people with schizophrenia
    Akanksha Sharma, Shoshana Buckhalter, Dan J. Siskind, David Jonathan Castle · 2022 · The Medical Journal of Australia
  7. Clozapine—serious adverse effects and clinical management
    Vlad Dionisie · 2024 · Elsevier eBooks
  8. Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia
    Júlio César Menezes Vieira, Edna Afonso Reis, Augusto Afonso Guerra, Helian Nunes de Oliveira, Cristina Mariano Ruas · 2024 · Frontiers in Psychiatry
  9. Improving the Monitoring and Management of Clozapine-Induced Gastrointestinal Hypomotility (CIGH) in Community Mental Health Services: A Quality Improvement Approach
    Balazs Adam, Osama Ayad · 2024 · Pharmacy
  10. Randomised controlled trial of clozapine in resistant schizophrenia and schizoaffective disorder
    Marc Peraire, Francisco Arnau, Mariano Villar-García, Ana Benito, Iván Echeverria, Gonzalo Haro · 2025 · Journal of Psychopharmacology
  11. Efficacy of clozapine for long‐stay patients with treatment‐resistant schizophrenia: 4‐year observational study
    Kentaro Mizuno, Emiko Mizuno, Akira Suekane, Toshiaki Shiratsuchi · 2022 · Neuropsychopharmacology Reports
  12. Role of primary care in supporting patients who are taking clozapine
    Taylan Yukselen, Jennifer Seal, Seema Varma, Harvey Wickham · 2019 · Drug and Therapeutics Bulletin
  13. Current Status of Clozapine for Treatment-Resistant Schizophrenia
    Se Hyun Kim · 2021 · Korean Journal of Schizophrenia Research
  14. Risk mitigation with the use of clozapine - Quo vadimus
    Satish Suhas, Amal Joseph Jolly, Swarna Buddha Nayok, Vanteemar Sathyanarayana Sreeraj, Vijay Kumar, Naren Prahalada Rao, Ganesan Venkatasubramanian · 2021 · Asian Journal of Psychiatry
  15. Management of clozapine-associated neutropenia
    Sumeet Gupta, Angela Bannon, Sunil Nodiyal, Baxi Neeraj Prasad Sinha · 2024 · BJPsych Advances
  16. Clozapine acceptance and refusal rates for inpatients vs. outpatients with schizophrenia– secondary analyses of real-world data from a Danish quality assurance and improvement audit
    Michelle Iris Jakobsen, Jimmi Nielsen · 2025 · Nordic Journal of Psychiatry
  17. Interpretable machine learning model for characterizing magnetic susceptibility-based biomarkers in first episode psychosis
    Pamela Franco, Cristián Montalba, Raúl Caulier‐Cisterna, Carlos Milovic, Alfonso González, Juan Pablo Ramírez-Mahaluf, Juan Pablo Undurraga, Rodrigo Salas, Nicolas Andres Crossley, Cristián Tejos N et al. · 2025 · Computer Methods and Programs in Biomedicine
  18. ACKR1 genetic testing should be offered before starting clozapine treatment
    Stephen Murtough, Daisy Mills, Noushin Saadullah Khani, Marius Cotic, Lauren Varney, Alvin Richards‐Belle, Rosemary Abidoph, Nicholas James Bass, Dharmisha Chauhan, Sarah R Curran et al. · 2026 · Nature Mental Health
  19. Risk of neutropenia-related hospitalisation among clozapine initiators
    Ameet Sarpatwari, Mufaddal Mahesri, Joyce Lii, Su Been Lee, Heidi Zakoul, Gita A. Toyserkani, Esther H. Zhou, Cynthia LaCivita, Gerald J. Dal Pan, Katsiaryna Bykov et al. · 2026 · BMJ Mental Health
  20. Involuntary Clozapine Treatment: A Systematic Review
    Hélène Verdoux, Alexis Lepetit, Peter F.J. Schulte · 2026 · Acta Psychiatrica Scandinavica
  21. Are the 8 Finnish Deaths Explained by Agranulocytosis More Important than the Thousands of Suicide Deaths Associated with the Lack of Use of Clozapine? Reflections on Clozaphobia
    José de León · 2026 · Journal of Clinical Psychopharmacology
  22. Performance in Practice: Practice Assessment Tool for the Care of Patients With Schizophrenia
    Laura J. Fochtmann, Jennifer Medicus, Seung-Hee Hong · 2020 · FOCUS The Journal of Lifelong Learning in Psychiatry
  23. Clozapine-induced diarrhoea: A case report of an unusual adverse reaction
    Nosa Godwin Igbinomwanhia, James Hunter MacCabe, David M. Taylor, Maria C. Lobo · 2022 · Psychiatry Research Case Reports
  24. Combination of strategies to initiate clozapine for refractory schizophrenia in a patient with low neutrophil levels
    Keisuke Takanobu, Naoki Hashimoto, Shuhei Ishikawa, Ichiro Kusumi · 2022 · BMJ Case Reports
  25. Causes or Cures: What makes us think of attention issues as disorders?
    Andreas DE BLOCK, Siegfried Dewitte, Kristien Hens · 2023 · New Ideas in Psychology
  26. Sicherheitsaspekte bei der Behandlung mit Clozapin:
    Stefan J. Berger, Alex Hofer · 2023 · Neuropsychiatrie
  27. Characterization of antipsychotic utilization before clozapine initiation for individuals with schizophrenia: an innovative visualization of trajectories using French National Health Insurance data
    Edouard‐Jules Laforgue, Marion Istvan, Anicet Chaslerie, Pascal Artarit, Geneviève Vallot, Pascale Jolliet, Marie Grall‐Bronnec, Caroline Victorri‐Vigneau · 2023 · Epidemiology and Psychiatric Sciences
  28. Developing a Clozapine Titration Monitoring Algorithm
    Emre Mutlu, Elçin Özçelik Eroğlu, Mevhibe İrem Yıldız, Doğukan Koçyiğit, Aygün Ertuğrul, Ayşe Elif Anil Yağcioğlu · 2025 · Journal of Clinical Psychopharmacology
  29. Clozapine utilization at the United States Veterans Health Administration: a descriptive report of prescribing patterns and patient characteristics among Operation Enduring Freedom/Operation Iraqi Freedom Veterans
    Zachary D. Zuschlag, Christopher A. Fowler, Andrew R. Devendorf, Vanessa Panaite, Olga Efimova, Susan K. Schultz · 2020 · International Clinical Psychopharmacology
  30. Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatment‐resistant schizophrenia
    Yumiko Akamine, Yuka Sugawara Kikuchi, Masatomo Miura · 2021 · Journal of Clinical Pharmacy and Therapeutics
  31. An International Adult Guideline for Making Clozapine Titration Safer by Using Ancestry-Based Personalized Dosing Titrations, C-Reactive Protein and Serum Clozapine Levels: Korean Translation and Its Clinical Application Cases
    Jung Su Park, Nuree Kang, Yong Min Ahn, Yong Sik Kim, Se Hyun Kim · 2023 · Korean Journal of Schizophrenia Research
  32. Dropped-Head syndrome: a possible new variant of clozapine-induced inflammation during titration
    Paula Jhoana Escobedo-Aedo, Irene Pans, Enrique Baca‐García, José de León, María Luisa Barrigón, Santiago Ovejero · 2024 · International Clinical Psychopharmacology
  33. Frequency of neutropenia over time in patients on clozapine
    Risha Govind, Amelia Jewell, Eromona Whiskey, Siobhan Gee, Ebenezer Oloyede, David M. Taylor, James Hunter MacCabe · 2022 · medRxiv
  34. Safer use of clozapine
    David M. Taylor · 2022 · Acta Psychiatrica Scandinavica
  35. Clozapine and the risk of haematological malignancies – Authors' reply
    Jari Tiihonen, Antti J. Tanskanen, J. Simon Bell, Jessica L. Dawson, Vesa V Kataja, Heidi T. Taipale · 2022 · The Lancet Psychiatry
  36. Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina
    José de León, Georgios Schoretsanitis, Robert L. Smith, Espen Molden, Anssi Solismaa, Niko Seppälä, Miloslav Kopeček, Patrik Švancer, Ismael Olmos, Carina Ricciardi et al. · 2023 · Psiquiatría Biológica
  37. The effects of individualism versus collectivism on clozapine policy stringency
    Alexander B. Cohn, Yvonne S. Yang · 2024 · Acta Psychiatrica Scandinavica
  38. Evaluating the impact of COVID-19 on medication adherence and health care utilization among individuals with psychotic disorders who are prescribed long-acting injectables (LAIs) or clozapine: A population-based study in Manitoba, Canada
    Yushi W. MacMillan-Wang, Jennifer M. Hensel, Christine Leong, Rajat Jayas, Eunice Valencia, Arianna Yorski, Kun Liu · 2024 · Schizophrenia Research
  39. Psychiatric Disorders and Cognitive Fluctuations in Parkinson’s Disease: Changing Approaches in the First Decades of the 21st Century
    MARCO C. ONOFRJ, Matteo Alessandro De Rosa, Mirella Russo, Paola Ajdinaj, Dario Calisi, Astrid Thomas, Stefano Luca Sensi · 2024 · Brain Sciences
  40. Premorbid school performance trajectories in patients with treatment-resistant schizophrenia prescribed clozapine in the public health system in Chile: a case-control study, 2007–2020
    José Conejeros‐Pavez, Javiera Vásquez Núñez, Camila Díaz, Cristián Mena, Juan Pablo Undurraga, Alfonso González‐Valderrama, Susana Claro, Eduardo A. Undurraga, Nicolas Andres Crossley · 2025 · Psychological Medicine
  41. Clozapine-Associated Pericarditis: A Systematic Review
    Aliu Opeyemi Yakubu, Olorungbami Kolade Anifalaje, Moses Gregory Effiong, Oluwakemi Eunice Olalude, Maryam O. Abubakar, Frederick Adeyemi · 2025 · Journal of the Academy of Consultation-Liaison Psychiatry
  42. The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations
    Geke van Weringh, Hans Joachim de Haas, Lieuwe de Haan, Daan Johannes Touw, Mariken Beatrijs de Koning · 2025 · European Journal of Drug Metabolism and Pharmacokinetics
  43. The duration of active psychosis and relationship with early psychosis outcomes
    Paul Crowley, Fiona Boland, Andrew Thompson, Patrick D. McGorry, Brian N. O'Donoghue, John Lyne · 2026 · Schizophrenia Research
  44. Adult psychiatrists’ views on clozapine prescribing for schizophrenia in Germany—an online survey
    Mishal Qubad, I.M. Ehret, Christian Bachmann, Robert A. Bittner · 2026 · Therapeutic Advances in Psychopharmacology
  45. Efficacy and Safety Outcomes of Different Plasma Clozapine and Norclozapine Levels in Schizophrenia Spectrum Disorder: A Dose-Response Meta-Analysis Exploring “critical” Levels
    Michele Fornaro, Chiara Di Lorenzo, Dan J. Siskind, Andrea de Bartolomeis · 2026 · Psychiatry Research
  46. Baseline neutrophil count, benign ethnic neutropenia risk, and clozapine haematological monitoring: A multi-ethnic retrospective cohort study from the United Arab Emirates
    Syed Ali Bokhari, Muhanad Elnoor, Mohamed Sabri, Mohammed Bardi, Faisal A. Nawaz, Syed Fahad Javaid · 2026 · Schizophrenia Research
  47. Temporal patterns and risk factors of clozapine-associated neutropenia: a nationwide population-based cohort study
    Chi‐Shin Wu, Korinne S. Northwood, Ming‐Shiang Wu, Shi‐Heng Wang, Wei‐Lieh Huang, Chen‐Chung Liu, Dan J. Siskind · 2026 · The Lancet Regional Health - Western Pacific
  48. An Updated Analysis of Psychotropic Medicine Utilisation in Older People in New Zealand from 2005 to 2019
    Prasad S. Nishtala, Te‐yuan Chyou · 2022 · Drugs & Aging
  49. Assessment and Management of Suicidal Risk
    Glenn Alexander Melvin, María A. Oquendo, Bárbara Stanley, Kelly Posner · 2023 · Springer eBooks
  50. Therapieresistente Schizophrenie
    Elias M. Wagner, Alkomiet Hasan · 2024 · PSYCH up2date
  51. Conference proceedings of the 4th Masterclass Psychiatry: Transcultural Psychiatry – Diagnostics and Treatment, Luleå, Sweden, 22–23 February 2018 (Region Norrbotten in collaboration with the Maudsley Hospital and Tavistock Clinic London)
    Ursula Werneke · 2018 · Nordic Journal of Psychiatry · Retracted
  52. Two-year cohort-up study of clozapine prescription in Chinese patients with schizophrenia treated in rural primary care
    Fei Wang, Zhuo‐Hui Huang, Christine Migliorini, Shibin Wang, Zi-Lang Chen, Qianwen Wang, Xiaoyan He, Carol Ann Harvey, Cai‐Lan Hou · 2022 · Asian Journal of Psychiatry
  53. A national pharmacovigilance study of haematological adverse drug reactions to clozapine vs other second–generation antipsychotics in Italy
    Sara Bertoli, Cecilia Casetta, Barbara Giordano, Armando D’Agostino · 2023 · Schizophrenia Research
  54. Large-scale analysis of DNA methylation identifies cellular alterations in blood from psychosis patients and molecular biomarkers of treatment-resistant schizophrenia
    Eilis J. Hannon, Emma Louise Dempster, Georgina Mansell, Joe Burrage, Nicholas James Bass, Marc M. Bohlken, Aiden Peter Corvin, Charles J. C. Curtis, David W. Dempster, Marta Di Forta et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  55. Informing Individualized Multi-Scale Neural Signatures of Clozapine Response in Patients with Treatment-Refractory Schizophrenia
    Jie Lisa Ji, Todd Lencz, Juan A. Gallego, Nicholas H. Neufeld, Aristotle N. Voineskos, Anil K. Malhotra, Alan Anticevic · 2023 · medRxiv
  56. When, Why and How to Re-challenge Clozapine following Myocarditis
    Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S. Martin, Valentina O. Püntmann, Eike C. Nagel, Andreas Reif, Robert A. Bittner · 2023
  57. What is the extent of research assessing patients’ and clinicians’ perspectives on clozapine treatment? – a comprehensive scoping review
    Michelle Iris Jakobsen, Julie Perrine Schaug, Ole Jakob Storebø, Stephen F. Austin, Jimmi Nielsen, Erik Hertel Simonsen · 2024 · medRxiv
  58. Does the evidence now suggest we can safely reduce the frequency of haematological monitoring for patients stabilised on clozapine?
    Jack B. Fanshawe, Belinda Lennox · 2024 · The Lancet Psychiatry
  59. Treating Unmet Needs in Psychiatry (TUNE-UP): A Targeted Service Increases Outpatient Initiations of Clozapine
    Z. Khan, I. Varvari, V. Mancini, C. Zauchenberger, S. Kantor, J. Fanshawe, S. Musiiwa, A. Pledge, B. Pearce, S. D. de La Motte et al. · 2025 · medRxiv
  60. Schizophrenia and Related Psychoses
    2025 · Wiley eBooks
  61. Prescription médicamenteuse en faveur de la réhabilitation
    Nicolas Franck B, Catherine Massoubre, Hélène Verdoux · 2018 · Elsevier eBooks
  62. Should Patients' Values Be Discussed in Relation to Long-Term Blood Monitoring Before and During Clozapine Treatment?
    Oddur Ingimarsson, James Hunter MacCabe, Magnus H. Haraldsson, Halldóra Jónsdóttir, Nanna Briem, Engilbert Sigurðsson · 2020 · Journal of Clinical Psychopharmacology
  63. An inquiry into various aspects of clozapine use
    Yvonne C. van der Zalm · 2021
  64. Towards personalized treatment of clozapine
    Cynthia Okhuijsen‐Pfeifer · 2021
  65. The Last Word: Beyond Toleration
    Edward W. James · 1985 · Journal of international women's studies
  66. 「情報生活論」序説 : 生活の情報化に関する生活者主体の理論枠設定の試み
    博介 水野 · 1993 · マス・コミュニケーション研究
  67. Clinical Practice and Cases in Emergency Medicine
    Nguyen, Trina · 2022 · Clinical Practice and Cases in Emergency Medicine
  68. Pattern of use of clozapine in Spain. Variability and under-prescription
    Francisco Javier Sanz-Fuentenebro, José Juan Uriarte Uriarte, Pere Bonet Dalmau, Vicente Molina, Miquel Bernardo Arroyo · 2019 · Revista de Psiquiatría y Salud Mental (English Edition)
  69. Comparison of the clinical features of patients with psychosis living in a nursing home or with their families, followed by the Community Mental Health Centers
    Batuhan Ayık, Hatice KAYA, Rümeysa Taşdelen, Alper Alnak, Muhammet Raşit AYDIN · 2022 · Sakarya Medical Journal
  70. The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry
    Robert A. Bittner, Andreas Reif, Mishal Qubad · 2023
  71. Supporting successful clozapine treatment
    Marieke Martine Beex-Oosterhuis · 2023
  72. Con qué medicamentos están siendo tratados los pacientes con trastorno afectivo bipolar en Colombia
    Jorge Enrique Machado-Alba, Alejandra Fonseca, Manuel Enrique Machado‐Duque, Viviana Calderón · 2023 · Universidad y Salud
  73. Un programme d’éducation thérapeutique pour l’initiation et le suivi d’un traitement par clozapine
    Mathilde Marquant, Anne-Laure Debruyne, Emmanuelle Queuille, Claire Boireau, Laurence Chagnoux, Emmanuelle Douriez, Laurence Gedon, Hélène Verdoux, Clélia Quilès · 2023 · Annales Médico-psychologiques revue psychiatrique
  74. CONSENSUS BY THE COLLECTIVE OF PSYCHIATRISTS FOR THE CLOZAPINE UPDATE.
    Miquel Bernardo, Emilio Fernández-Egea · 2023 · PubMed Central
  75. The 2022 Incentive Award of the Okayama Medical Association in Neuroscience (2022 Niimi Prize)
    Yuji Yada · 2023 · Okayama Igakkai Zasshi (Journal of Okayama Medical Association)
  76. An expert Delphi consensus for the characteristics of an ideal clozapine-specific side effect scale
    Emilio Fernández-Egea, Miquel Bernardo · 2024 · The European Journal of Psychiatry
  77. Assessment and Management of Suicidal Risk
    Glenn Alexander Melvin, María A. Oquendo, Bárbara Stanley, Kelly Posner · 2024 · Springer eBooks
  78. Surveillance hématologique de la clozapine : les temps sont-ils venus d’assouplir les règles ?
    Hélène Verdoux, Alexis Lepetit · 2024 · Annales Médico-psychologiques revue psychiatrique
  79. Delivery and delay of guideline pharmacological, psychological, and social interventions for adults with complex psychosis in Dutch inpatient rehabilitation units: A retrospective study
    Thijs Jan Burger, Hans J. de Haas, Robin Michael Van Eck, Martijn Kikkert, Frederike N. Schirmbeck, Astrid Vellinga, Lieuwe de Haan, Mariken Beatrijs de Koning · 2025 · International Journal of Social Psychiatry
  80. Are cognitive deficits more severe among people with treatment-resistant schizophrenia than treatment responders?
    Ananthakrishnan Koloth, Kim Yeak, Somayyeh Azimi, Radhakrishnan Koloth, A.L. Alexander, Milan Dragović, Alexander Panickacheril John · 2025 · Australasian Psychiatry
  81. Perceived Experience of the clozapine Treatment Protocol: A Qualitative Study of Reports by Brazilian Patients With Schizophrenia Treated in a University Outpatient Service Specializing in Psychiatry
    Jo Santos, Francisco Carlos Specian, L. S. Valladão, Paulo Dalgalarrondo, Clarissa de Rosalmeida Dantas, Egberto Ribeiro Turato · 2025 · Brain and Behavior
  82. Factors Affecting Clozapine Adherence in Patients With Schizophrenia: A Qualitative Study
    Sung Moon Choi, Myungjae Baik, Won Sub Kang, Ah Rah Lee, Jong‐Woo Paik, Sang Min Lee · 2025 · 신경정신의학
  83. Additional file 1 of Overview of lithium's use: a nationwide survey
    Xabier Pérez de Mendiola Etxezarraga, Hidalgo-Mazzei, Diego, Vieta, Eduard, González-Pinto, Ana · 2021 · Figshare
  84. Additional file 1 of History of suicidal behavior and clozapine prescribing among people with schizophrenia in China: a cohort study
    Yi Yin, Lin, Chen, Lijing Wei, Tong, Jinghui, Junchao Huang, Baopeng Tian, Tan, Shuping, Wang, Zhiren, Yang, Fude, Tong, Yongsheng et al. · 2024 · Figshare
  85. Restoring decision‐making capacity through ECT to enable clozapine initiation in treatment‐resistant schizophrenia: An ethical and clinical case report
    Shimpei Hanaoka, Hiroki Suzuki, Akira Sugeno · 2026 · Psychiatry and Clinical Neurosciences Reports
  86. Clozapine-induced Myocarditis in Korea: Analysis of a Nationwide Database and Comparison to Other Countries
    Jeonghoon Lee, Hyunsu Jeong, Jung Su Park, Nuree Kang, Jae Hoon Jeong, Se Hyun Kim · 2026 · Clinical Psychopharmacology and Neuroscience
  87. Reply to “Beyond Clozapine: Addressing Broader Metabolic Burden in Treatment-Resistant Schizophrenia“
    Alexander Panickacheril John, Hitesh Prajapati, Milan Dragović · 2026 · Journal of Clinical Psychopharmacology
  88. Therapieresistente Schizophrenie
    Elias M. Wagner, Alkomiet Hasan · 2026 · Nervenheilkunde
  89. Treating Unmet Needs in Psychiatry (TUNE-UP): targeted service increases out-patient initiations of clozapine
    Zmarak Ahmad Khan, I. Varvari, V. Mancini, Chambrez Zita-Zauchenberger, S. Kantor, J. Fanshawe, S. Musiiwa, A. Pledge, B. Pearce, Saïk J. G. N. de La Motte de Broöns de Vauvert et al. · 2026 · BJPsych Open
  90. Genetic evidence for causal relationship between general cognition and treatment resistance in schizophrenia
    Chao Li, Yuanxin Zhong, P. Sham, S. Chan · 2026 · Translational Psychiatry
  91. Consommation de psychotropes et de soins en santé mentale à la suite d'un événement traumatique de masse : une approche pharmaco-épidémiologique centrée sur l'enfant et l'adolescent à partir du Système National des Données de Santé
    Alexis Revet · 2021
  92. Clozapine underutilization in Saudi Arabia: insights from a national survey of psychiatrists and implications for clinical training and practice
    Muath M Alqarni, Ahad R Almuallim, Yasemin Y. Demiroz, Hussain Khrad, Rozan Omdah, Hanady Gouta, Ahmad S. Alzahrani · 2026 · International Journal of Psychiatry in Clinical Practice
  93. Prevalence of antipsychotic polypharmacy in patients with schizophrenia and other psychotic disorders in the MENAT and EMRO countries: a systematic review and meta-analysis
    Mohammed A. Alhassan, Mohammed Alarabi, Waled M. Albalawi, Thenuwara Arachchige Omila Kasun Meetiyagoda, Anum Nisar, Wondim Alemu Ayenew, Fatimah Adnan Shehab, Gary J. Remington · 2026 · Frontiers in Psychiatry
  94. Proportion and Reasons for Clozapine Discontinuation: A Systematic Review and Meta-Analysis
    Paul McLaughlin, Róisín McManus, Oisín Conaty, Faisal Al-Harbi, Fiona Gaughran, Brian N. O'Donoghue, John Lally · 2026 · Schizophrenia Bulletin Open
  95. Lumateperone as an alternative to clozapine in treatment-resistant schizophrenia: Insights from a quantitative systems pharmacology model
    Archana Mishra, Biswa Ranjan Mishra, Rituparna Maiti, Debasish Hota · 2026 · Journal of Pharmacology and Experimental Therapeutics
  96. Therapeutic Interventions and Clinical Outcomes Following Breakthrough Psychosis on Antipsychotic Maintenance Medication (BAMM): A Retrospective Chart Review.
    F. Misawa, H. Takeuchi · 2026 · Journal of Clinical Psychopharmacology
  97. Factors associated with social functioning by relapse frequency in Japanese outpatients with schizophrenia: the Multicenter Treatment Survey and Assessments for Schizophrenia in Psychiatric Clinics (MUSASI)
    Yoshiteru Takekita, Eiichi Katsumoto, Naoto Adachi, Yukihisa Kubota, Koji Edagawa, Takaharu Azekawa, Hitoshi Ueda, Tatsuji Tamura, Seiji Hongo, Eiichiro Goto et al. · 2026 · Psychological Medicine
  98. Real-world antipsychotic prescribing pathways and treatment modifications in schizophrenia spectrum disorders: evidence from the United Arab Emirates
    Syed Ali Bokhari, Muhanad Elnoor, Syed Fahad Javaid, Mohamed Abdalhameed Alnor · 2026 · Frontiers in Pharmacology
  99. Relaxation of Japan's clozapine monitoring system is urgently needed: Adding 10,000 future prescriptions may prevent up to 400 schizophrenia‐related suicides and cost 1 death by agranulocytosis
    José de León, Yuki Kikuchi, Norio Yasui‐Furukori · 2026 · Psychiatry and Clinical Neurosciences Reports
  100. Twenty-Year Trends in Antipsychotic Utilization in Serbia: A Nationwide Drug Utilization Study
    Zorana Pavlović, Milena Stevanovic, Marija Milić, Jelena Subaric Filimonovic, Bojana Matejić, Mladen Bogdanović, Ivana Vukajlovic, Aleksandar Krstić, Miodrag S. Milenovic, Bojana Dunjić-Kostić · 2026 · Pharmaceuticals